Key facts
- This page summarizes Michael Derby's Form 4 filing for PaxMedica, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Mar 2023, 18:17.
Michael Derby - 06 Mar 2023 Form 4 Insider Report for PaxMedica, Inc.
- Reporting relationship
- Executive Chairman, Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 06 Mar 2023
- Net transaction value
- -$47,242
- SEC form
- 4
- Accepted by SEC
- 07 Mar 2023, 18:17:12 UTC
- Prior SEC filing
- 03 Mar 2023
- Next SEC filing
- 09 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen D. Sheldon, Jr. Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Derby filed Form 4 for PaxMedica, Inc. on 07 Mar 2023.
Change
- Previous filing in this sequence was filed on 03 Mar 2023.
- Current net transaction value: -$47,242.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PXMD
transaction
Common Stock
Sale
- Transaction value
- $23,784
- Shares
- -13,828
- Change %
- -3.9%
- Price
- $1.72
- Shares after
- 341,707
- Date
- 06 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
PXMD
transaction
Common Stock
Sale
- Transaction value
- $23,458
- Shares
- -15,134
- Change %
- -4.4%
- Price
- $1.55
- Shares after
- 326,573
- Date
- 07 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F3
PXMD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,336,745
- Date
- 06 Mar 2023
- Ownership
- TardiMed Sciences, LLC
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan. Shares were sold by the Reporting Person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of restricted stock units granted to the Reporting Person.
Footnote F2
This sale price represents the weighted average sale price of the shares sold ranging from $1.90 to $1.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Footnote F3
This sale price represents the weighted average sale price of the shares sold ranging from $1.67 to $1.45 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Footnote F4
The reporting person is the Managing Partner of TardiMed and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.